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Abstract
Retroviral vector-mediated gene transfer has been central to the development of gene therapy.
Retroviruses have several distinct advantages over other vectors, especially when permanent gene transfer
is the preferred outcome. The most important advantage that retroviral vectors offer is their ability to
transform their single stranded RNA genome into a double stranded DNA molecule that stably integrates
into the target cell genome. This means that retroviral vectors can be used to permanently modify the host
cell nuclear genome. Recently, retroviral vector-mediated gene transfer, as well as the broader gene
therapy field, has been re-invigorated with the development of a new class of retroviral vectors which are
derived from lentiviruses. These have the unique ability amongst retroviruses of being able to infect non-
cycling cells. Vectors derived from lentiviruses have provided a quantum leap in technology and seemingly
offer the means to achieve significant levels of gene transfer in vivo.
The ability of retroviruses to integrate into the host cell chromosome also raises the possibility of
insertional mutagenesis and oncogene activation. Both these phenomena are well known in the
interactions of certain types of wild-type retroviruses with their hosts. However, until recently they had
not been observed in replication defective retroviral vector-mediated gene transfer, either in animal
models or in clinical trials. This has meant the potential disadvantages of retroviral mediated gene therapy
have, until recently, been seen as largely, if not entirely, hypothetical. The recent clinical trial of γc mediated
gene therapy for X-linked severe combined immunodeficiency (X-SCID) has proven the potential of
retroviral mediated gene transfer for the treatment of inherited metabolic disease. However, it has also
illustrated the potential dangers involved, with 2 out of 10 patients developing T cell leukemia as a
consequence of the treatment. A considered review of retroviral induced pathogenesis suggests these
events were qualitatively, if not quantitatively, predictable. In addition, it is clear that the probability of such
events can be greatly reduced by relatively simple vector modifications, such as the use of self-inactivating
vectors and vectors derived from non-oncogenic retroviruses. However, these approaches remain to be
fully developed and validated. This review also suggests that, in all likelihood, there are no other major
retroviral pathogenetic mechanisms that are of general relevance to replication defective retroviral
vectors. These are important conclusions as they suggest that, by careful design and engineering of
retroviral vectors, we can continue to use this gene transfer technology with confidence.
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Background
Retroviruses
Retroviruses are viruses that are found throughout the ani-
mal kingdom, including in chickens, mice, cats, sheep,
goats, cattle, primates, fish and humans. The first retro
viruses were identified as cell free oncogenic factors in
chickens. Subsequently, many of the oncogenic retrovi-
ruses have been shown to be replication defective forms
that have substituted a part of their normal viral gene
complement with an oncogene sequence [1]. Replication
competent retroviruses also cause malignant disease, as
well as a range of other pathogenic states, in a broad range
of species. This includes what must be the most significant
transmissible disease of humans in recent times, acquired
immunodeficiency syndrome (AIDS), which is caused by
the retroviruses Human Immunodeficiency Virus Types 1
and 2 (HIV-1, HIV-2). However, many retroviruses cause
life-long infections and appear to be relatively, if not com-
pletely benign, in their normal host species. In mice there
are retroviruses that are very closely related to strongly
oncogenic retroviruses but which are not themselves
oncogenic, or are only very weakly oncogenic [2-5]. In
addition, there is a whole class of retroviruses, the spuma-
viruses, or foamy viruses, which do not appear to be
linked to any specific pathogenic state [6]. Even the sim-
ian equivalent of HIV-1, the causative agent of AIDS, is
not pathogenic in all its hosts [7]. There is also a range of
endogenous retroviral sequences that are not associated
with specific pathologies [8]. Vestigial forms of retrovi-
ruses also exist; these are represented by various classes of
insertional elements and can constitute a significant pro-
portion of animal genomes [8].
The retroviral virion is a spherical particle of about 80–
100 nm in diameter. It is enclosed by a lipid bilayer
derived from the host cell plasma membrane into which
one of the retroviral gene products, the envelope protein,
is inserted. The virion has considerable internal structure
that is mainly comprised of the products of the viral gag
gene. In addition, the virion contains two identical copies
of a genomic RNA molecule (the retrovirus is then genet-
ically haploid but can also be described as pseudo-dip-
loid), a tRNA primer for reverse transcription as well as
small amounts of the products of the viral pol gene. The
virion may also include a range of other host cell derived
proteins although it is unclear whether these represent a
random assortment of proteins that are coincidently
incorporated into the virion or whether they play some
role in the viral life cycle. Both possibilities are probably
true, certainly HIV-1 is known to incorporate into its vir-
ion a number of host cell proteins that play a vital role in
its life cycle [9,10].
While the simple retroviruses have only three genes, gag,
pol and env, the complex retroviruses encode a number of
other proteins that are involved in regulating viral replica-
tion or the host cells response to the virus. For example,
HIV-1 has six gene sequences in addition to the minimal
retroviral complement of gag, pol and env. Two of these, tat
and rev, encode proteins that regulate expression of the
viral genome, while the other four, vpu, vif, vpr and nef,
encode proteins that play multiple roles in enhancing
viral replication.
Retroviral life cycle
It is the unique nature of the retroviral life cycle, com-
bined with the simplicity and advantageous arrangement
of the retroviral genome, which has made retroviruses so
attractive as vectors for gene therapy [11,12]. The princi-
pal feature of the retroviral life cycle that is of interest is
the ability of the retrovirus to copy its RNA genome into a
double-stranded DNA form which is then efficiently and
exactly integrated into the host cell genome. The inte-
grated form is termed the provirus and it is transcribed as
a normal cellular gene to produce both mRNAs encoding
the various viral proteins, and the genomic RNA that is
packaged into progeny virions.
The genetic structure of the virus and the existence of the
proviral form make it easy to manipulate retroviruses to
make replication defective vectors for transfer of heterolo-
gous gene sequences. The proviral form, being DNA, can
be readily isolated in standard plasmid cloning vectors
The cis and trans genetic functions of a retrovirus Figure 1
The cis and trans genetic functions of a retrovirus. Cis 
sequences (shown in black) are those that are directly active 
as nucleic acids, they include the 5' long terminal repeat 
(LTR) which, in the DNA form found in the provirus acts as a 
transcriptional promoter, and in the RNA (genomic) form 
contains sequences important for reverse transcription of 
the genome; the primer binding site (PBS) for first strand 
DNA synthesis during reverse transcription; the psi (ψ) 
sequence which directs packaging of the genomic RNA into 
the virion; the polypurine tract (ppt) which is the primer 
binding site for second strand DNA synthesis during reverse 
transcription and the 3' LTR which, in the DNA form (in the 
provirus) acts as a polyadenylation signal, and in the RNA 
(genomic) form contains sequences important for the 
reverse transcription process. The trans functions (shown in 
green) are the protein coding sequences, these are the gagpol 
gene, which encodes the Gag and Pol polyproteins, and the 
env gene that encodes the viral envelope protein.
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and so made amenable to molecular manipulation. The
genetic structure of the virus is such that the viral cis
(sequences that are biologically active in the form of
nucleic acids) and trans (protein coding sequences) func-
tions (Fig. 1) are largely non-overlapping; indeed, as far as
recombinant vectors are concerned it is possible to sepa-
rate them completely, albeit at some cost in efficiency. The
generation of systems capable of producing non-replica-
tion competent virus can then be achieved by placing the
cis elements on a transfer vector construct and expressing
the trans functions using standard recombinant plasmid
expression systems (Fig. 2). As the genomic RNA
expressed from the transfer vector construct is the only
RNA molecule that carries the cis signals required for pack-
aging into the virion, and for reverse transcription and
integration, no viral genes are transferred to cells infected
with the resulting virus. The resulting provirus, lacking all
viral genes, is a replicative dead end and no further viral
replication is possible. The nature of the retroviral replica-
tion process, where the U3 region of both the 5' and 3'
LTRs of the provirus are effectively copied from the 3' LTR
of the provirus in the preceding generation, also makes
possible the construction of self-inactivating (SIN) vec-
tors. With these vectors the resulting provirus contains no
active retroviral derived transcriptional promoter or
enhancer elements [13,14].
The use of a replication-defective retroviral vector to trans-
fer gene sequences into target cells has been termed trans-
duction, to distinguish it from the process of infection with
replication competent viruses. It is theoretically possible
that with most, if not all, recombinant vector systems, that
recombination of the constituent parts of the system with
each other, or with cellular sequences, can regenerate a
replication competent retrovirus (RCR) [15,16]. However,
the careful engineering of these systems has led to the
point where they can largely be assumed to be free of such
RCR. While this does not mean that screening for RCR in
preparations of vector is unimportant, as there are a
number of other ways in which RCR may arise, and as
quality control is obviously central to the clinical use of
retroviral vectors, it does mean that in practice RCR gener-
ation should no longer be a major safety issue. This means
that in terms of evaluating the safety of retroviral vectors
it is the direct and indirect consequences of proviral inte-
gration that are important to consider, rather than the
effects of actively replicating virus.
Retroviral mediated pathogenesis
Retroviruses have historically been most intensively stud-
ied in animals that are either the subject of scientific
experimentation (principally the laboratory mouse), or
are of commercial significance (such as farmed animals
such as chickens, horses, goats, cattle and fish, and pets),
where they cause a number of commercially significant
diseases. Indeed, the first retroviruses to be described were
the oncogenic retroviruses Avian leukosis virus (ALV), and
Rous sarcoma virus (RSV), which are both found in chick-
ens. A large number of oncogenic retroviruses have now
been described. These tend to cause malignant disease in
a very high proportion of infected hosts. In addition, the
complex retroviruses human T-cell leukemia virus (HTLV)
and bovine leukemia virus (BLV) can cause leukemia in
their hosts, although they do so in only a small percentage
of infected individuals.
The lentiviruses are also overtly pathogenic and have been
shown to be the causative agent of several slow progres-
sive diseases in animals including arthritis and encephali-
tis in goats, leukemia in cattle, anaemia in horses, and
immunodeficiency in cats, cattle, primates and humans.
The AIDS epidemic means that the lentivirus HIV-1 is now
the most intensively studied retrovirus ever-incredibly,
given the relative genetic simplicity of the retroviruses,
there appears to be much still to learn about many aspects
of HIV-1. There are also a number of viruses that cause
central nervous system (CNS) pathology. For some of
Separation of the cis and trans functions of a retrovirus in a  recombinant, replication defective vector system Figure 2
Separation of the cis and trans functions of a retrovi-
rus in a recombinant, replication defective vector 
system. Replication defective retroviral vector systems are 
made by separating the cis (shown in black) and trans (shown 
in green) genetic functions of the virus into a vector con-
struct, which contains the cis sequences, and helper or pack-
aging plasmids, that encode the viral proteins (i.e. contain the 
trans sequences). To minimize overlap between the two 
components of the system heterologous transcriptional con-
trol elements (shown in red) are used to express the trans 
functions. Recombinant virus is made by introducing all these 
elements into the same cell. Only the vector transcript is 
incorporated into virions as this is the only RNA that con-
tains the retroviral packaging signal (ψ).
gagpol
poly(a)
poly(a)
env
P
B
S
ψ
ψ
ψ
ψ
p
p
t
LTR LTR Transgene cassetteGenetic Vaccines and Therapy 2004, 2:9 http://www.gvt-journal.com/content/2/1/9
Page 4 of 13
(page number not for citation purposes)
these, such as HIV and HTLV, CNS disease is a secondary
pathology, while others are more specific in their effects.
Similarly, while ALV and RSV are best known as onco-
genic viruses, they are also associated with wasting
syndromes.
Oncogenic retroviruses
The archetypal retroviral pathogen is the oncogenic retro-
virus. Some of these are replication defective retroviruses
that carry and express an oncogene sequence-indeed it
was these retroviruses that largely allowed the concept of
oncogenes to be first defined. These viruses induce cancers
with relatively short latency periods. In addition, there are
a large number of non-defective retroviruses that are
oncogenic. These generally induce cancers after longer
latency periods. HTLV and BLV and related viruses form a
separate class of complex retroviruses that cause leukemia
in a small percentage of infected individuals after very
long latency periods. Retroviruses have also been associ-
ated with sarcomas in fish but these viruses have not been
studied in great detail.
Defective oncogenic retroviruses
These have been described in a number of species, but
have been most extensively studied in the laboratory
mouse. These are replication defective, simple retroviruses
in which part of the normal viral genome has been
replaced with a cDNA copy of a cellular oncogene. The
viral oncogene sequence often contains mutations that
make the protein it encodes act in a dominant manner.
The capture of a cellular oncogene by a retrovirus is an
extremely rare event, the major significance of these
viruses in scientific terms is that they led to the discovery
of cellular oncogenes. These viruses depend on the pres-
ence of a replication competent helper virus in order to
replicate and they induce cancers with relatively short
latency periods. The existence of a latency period suggests
that oncogene expression is, in itself, not enough to cause
malignant disease, but that additional genetic events are
required. The majority of the cancers caused by these ret-
roviruses are found in the haematopoietic system
although sarcomas are also common. They are also able to
transform the phenotype of cells grown in culture, princi-
pally by causing cells to lose their contact inhibition. The
type of malignant event caused by any one virus is deter-
mined by the nature of the oncogene expressed by the
virus and by the nature of the enhancer sequences present
in the long terminal repeat which control the tissue spe-
cific expression of the oncogene.
Replication defective vectors obviously also have the same
potential to capture oncogenes. However, the mechanism
of oncogene capture by retroviruses, and its extreme rarity,
means it is probably not of major relevance when consid-
ering the risk factors associated with the use of retroviral
vectors for gene therapy.
Non-defective oncogenic retroviruses
Non-defective, replication competent retroviruses are also
associated with malignant diseases. These viruses do not
carry oncogene sequences. Although first discovered in
the chicken they have been most extensively studied in the
laboratory mouse. These viruses induce cancer by activat-
ing cellular oncogenes via a number of different mecha-
nisms. In contrast to the oncogene carrying retroviruses,
these viruses are associated with much longer latency peri-
ods. This is a reflection of the relatively low probability
that proviral insertion will result in activation of an onco-
gene, in combination with the requirement for other
genetic changes before a cancer eventuates. Although pro-
viral integration can also result in gene inactivation, inac-
tivation of tumour suppressor genes does not appear to be
a mechanism associated with any known instances of ret-
roviral induced malignancy.
The principal routes of oncogene activation are transcrip-
tional promotion from one of the viral LTRs, and activa-
tion of endogenous cellular promoters by the strong
transcriptional enhancer elements present in the viral
LTRs. In the former case the provirus must obviously inte-
grate in the sense orientation and upstream of the relevant
coding sequence. Transcription can be from either LTR
[17], and may involve splicing from either the retroviral,
or cryptic, splice donor sites to a splice acceptor within the
gene sequence [17]. If transcription is from the 3' LTR it is
usually associated with inactivating mutations in the 5'
LTR [18]. Transcriptional enhancement can occur with the
provirus in either orientation [19] and over relatively large
distances [20,21]. This is by far the most common mech-
anism of oncogene activation. Another mechanism by
which proviral integration can activate cellular oncogenes
is by negation of negative regulatory elements in the onco-
gene or its transcript [22]. However, this is a rare phenom-
enon. If proviral integration is downstream of the
oncogene translation initiation codon a dominant variant
of the oncogene product may result [23].
Not all non-defective simple retroviruses are overtly onco-
genic and the oncogenic, non-defective simple retrovi-
ruses show a spectrum of tissue specificity and oncogenic
potential. Analysis of the oncogenic potential of different
retroviruses has clearly shown that the major determinant
of both the overall oncogenic potential of the virus, and
the cell specificity of the type of cancer that results, is the
viral long terminal repeat [24-27]. More specifically, it is
the transcriptional enhancer sequences in the long termi-
nal repeat that are the major determinant of these proper-
ties [28-33]. Mechanistically, this makes perfect sense. As
transcriptional enhancer elements are capable of acting atGenetic Vaccines and Therapy 2004, 2:9 http://www.gvt-journal.com/content/2/1/9
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a distance they will not only control transcription from
the viral LTR but will also have the potential to influence
transcription from promoter sequences in adjacent chro-
mosomal genes.
In contrast to oncogene activation, the oncogenic poten-
tial of some retroviruses maps to the env gene sequences.
For example, the SU protein (p55) of the polycythemic
strain of Friend virus binds to, and activates, the erythro-
poietin receptor resulting in massive erythroid prolifera-
tion and splenomegaly [34]. However, p55 does not bind
to the active site of the Epo receptor and the Epo receptor
is not used as the receptor for virus infection. In fact, p55
is not a functional envelope for infection and a helper
virus is needed to allow the virus encoding p55 to propa-
gate itself. In an analogous manner, the sag  gene of
Murine Mammary Tumour Viruses (MMTV) induces an
immune response by interacting with the T-cell receptor
[35]. This does not result in leukemia but facilitates the
eventual induction of malignant disease in an indirect
way. As the interaction between Sag and the T-cell receptor
is not via the antigen binding site itself, a large proportion
of the T-cell population (up to 10%) is stimulated. This,
in turn, stimulates B-cells, the initial cellular target for
infecting MMTV, allowing enhanced viral replication and
the subsequent infection of mammary epithelial cells, the
eventual site of tumour formation. Although Sag is a
major determinant of the oncogenic potential of MMTV it
should be noted that in the final analysis malignancy is
due to oncogene activation.
How HTLV [36] and BLV cause cancer is not entirely clear.
Both are complex retroviruses, and in addition to the gag,
pol and env genes common to all retroviruses, have two
genes that encode regulatory proteins. HTLV causes adult
T-cell leukemia, often after a very long latency period (two
or three decades can pass between infection and emer-
gence of malignant disease). Only a small percentage of
infected individuals (about 1% for HTLV) develop cancer.
Although the mechanism of disease induction is unclear it
is certainly related to the clonal proliferation of infected
cells  in vivo. Although viral gene expression does not
appear to be necessary for maintenance of the disease,
evidence suggests that one of the regulatory proteins, Tax,
is important in inducing the initial T cell proliferation.
Given the recent development of vectors from lentivi-
ruses, including HIV, it is worth noting that despite
intense scientific scrutiny, examples of insertional muta-
genesis or gene activation resulting from infection with
these viruses have not been documented. However, in the
case of HIV-1 the limited lifespan of most infected cells
means that this observation must be interpreted with
caution.
In terms of replication defective retroviral vectors, the
study of oncogenic retroviruses suggests that oncogene
activation,  via  the provision of promoter or enhancer
sequences, but especially the latter, will be the major risk
factor for disease induction. In addition, selection of the
retroviral envelope used for vector pseudotyping could
also potentially play a role as could inadvertent transfer
and expression of other retroviral proteins, at least for vec-
tors developed from particular retroviruses, such as Friend
virus.
Retroviruses causing CNS disease
Several retroviruses cause CNS disease. Some of these,
such as the murine retroviruses Cas-Br-E MLV [37] and
FMCF98 [38] are specifically associated with CNS pathol-
ogy. For other retroviruses, such as HTLV and HIV, CNS
disease is not the defining pathology induced by the virus,
even though for the latter a high proportion of infected
individuals will develop CNS disease. Cas-Br-E MLV
infects the brain via infection of the epithelial cells of the
blood-brain barrier. After these become infected they
release virus directly into the CNS where it infects micro-
glial cells, resulting in a spongiform encephalopathy. The
SU (env) protein has been shown to be a major determi-
nant of the neuropathogenesis of Cas-Br-E MLV [39] and
other neuropathogenic murine retroviruses. However, the
mechanisms involved have not been elucidated although
receptor activation [40], analogous to that caused by the
SU protein of the polycythemic strain of Friend virus, has
been suggested but as yet remains unproven.
HTLV causes CNS disease in only a small percentage
(about 1%) of infected individuals after a latent period
that can be as short as two, or as long as thirty years [41].
The development of CNS disease is not correlated with the
development of ATL. For HTLV CNS disease is character-
ised by a vigorous inflammatory response involving T
cells that causes severe demyelination in the spinal cord.
Little is known about how the virus infects the CNS and
what cell types are infected, or what factors influence the
induction of CNS pathology.
Most individuals infected with HIV have virus within the
CNS and the route of infection is thought to be transmi-
gration of infected macrophages across the blood-brain
barrier. As well as allowing opportunistic infections
within the CNS there is a specific condition, AIDS demen-
tia complex (ADC), which is a direct result of HIV infec-
tion of the CNS [42]. Within the CNS HIV is found in
macrophages and microglia, and causes demyelination,
vacuolation and gliosis. Again, the mechanism by which
HIV causes CNS pathology is not well understood. The
gp120 (Env) and Tat proteins have been shown to be neu-
rotoxic in vitro and a number of the cytokines induced by
HIV infection of monocytes and macrophages also haveGenetic Vaccines and Therapy 2004, 2:9 http://www.gvt-journal.com/content/2/1/9
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the capacity to damage neural tissue, either directly or
indirectly [43].
All of the retroviruses that cause CNS disease would
appear to do so as a consequence of their active replica-
tion. In the case of HIV there is direct evidence for this-
treatment of patients with antiretrovirals can significantly
decrease the severity of CNS disease [44]. However,
aspects of CNS pathology remain unresolved, for example
HIV encephalitis persists even during highly active anti-
retroviral therapy [45]. Therefore, this area of retrovirus
induced pathology does not appear to be of immediate
relevance to replication defective retroviral vectors. How-
ever, until the mechanisms by which some aspects of CNS
pathology are induced are better understood this facet of
retroviral pathogenesis cannot be entirely dismissed in
terms of its relevance to the design and use of retroviral
vectors.
Retroviruses causing immuno-deficiencies
The AIDS epidemic has brought a substantial focus to bear
on the retroviruses that cause immunodeficiencies in gen-
eral, and the subset of these that are lentiviruses in partic-
ular. Simple retroviruses that cause immune deficiencies
in mice [46], cats [47] and primates [48,49] have been
described. Somewhat surprisingly, the pathological mech-
anisms in these diseases are all different. In mice, immu-
nodeficiency is associated with proliferation of B cells (the
primary target of infection), macrophages and CD4+ T-
cells, all of which are non-functional. The disease is con-
sistent with the development of anergy after antigen
driven stimulation of the immune response [50]. Expres-
sion of a mutant gag gene product, Pr60 Gag, which is not
processed normally [51], is required for induction of dis-
ease. However, the pathogenetic mechanisms involved
are not understood. The defect in Gag processing makes
the virus replication defective and a helper virus is
required for virus spread, although not for induction of
disease [52].
In cats the simple retroviruses that induce immunodefi-
ciency do so via expression of an altered SU (Env) protein.
This protein is incapable of causing resistance to superin-
fection [53]; as a consequence repeated superinfection
leads directly to T cell lysis [54] and immunodeficiency
then results due to a loss of T-cell function.
The lentiviruses that have been associated with immune
deficiency are FIV, SIV and HIV. All appear to share a com-
mon pathogenetic mechanism where virus infection of,
and replication in, T-cells directly causes cell death, T-cell
depletion and immunodeficiency [55]. Cell death is
caused by high levels of viral replication in infected cells,
although the exact mechanism is unclear. However, it is
also clear that the pathogenesis of HIV-1 infection is much
more complicated than this, with a complex interaction
between the virus and host being played out over time
[56]. In some non-human primates, infection with SIV is
usually a chronic, but largely asymptomatic, condition
[7]. This is thought to reflect a host/virus balance that has
evolved over a long period of time. Presumably, the
human AIDS epidemic reflects a recent movement of HIV
into the population with a resulting imbalance between
viral pathogenicity and host defences, which, after a rela-
tively long period of infection, is resolved in favour of the
pathogen.
Again, the pathogenetic mechanisms involved with these
retroviruses do not have major relevance to replication
defective retroviral vectors. However, the pathogenetic
mechanisms involved in the murine and feline immuno-
deficiencies caused by simple retroviruses do reiterate the
point that expression of certain retroviral gene products
can induce serious pathogenetic states and that this fact
may have some relevance to vector design.
Lentiviruses
Apart from the lentiviruses mentioned above that result in
immunodeficiency, there are a number of other lentiviral-
associated diseases including those caused by caprine
arthritis encephalitis virus (CAEV) [57], equine infectious
anemia virus (EIAV) [58] and maedi/visna virus (MVV)
[59]. For CAEV and MMV viral infection of macrophages
seems to induce an inflammatory response involving
macrophages and CD4+ and CD8+ T cells. It is this
inflammatory response that is responsible for the differ-
ent aspects of the pathology associated with infection by
these viruses. EIAV causes erythrocyte lysis when high
titres of cell free virus are present in the circulation. There
are several mechanisms involved. Direct interaction of
EIAV particles and erythrocytes results in complement
mediated lysis and macrophage engulfment. This interac-
tion is probably mediated by the Env protein. In addition,
the virus appears able to suppress the differentiation of
erythroid precursors. Eventually, most animals become
asymptomatic carriers six to twelve months after
infection.
For all these viruses pathology appears to be intimately
linked to viral replication. Therefore, the pathological
mechanisms involved are not of direct relevance to repli-
cation defective retroviral vectors.
Other retrovirus induced pathologies
Retroviral infection has also been shown to be the cause
of wasting and osteopetrosis in birds [60] and anaemia in
cats [61]. Apart from feline anaemia, where the SU (Env)
protein is a major, although not the sole determinant for
the determination of pathology, the disease mechanisms
involved are not well understood. However, pathology isGenetic Vaccines and Therapy 2004, 2:9 http://www.gvt-journal.com/content/2/1/9
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clearly dependent on sustained viral replication meaning
its significance to replication defective vectors is again
limited.
Pathogenic potential of retroviral vectors
From the known mechanisms of retroviral pathogenesis
discussed above the most obvious pathogenic potential of
retroviral vectors is (i) the production of a replication
competent virus, and (ii) insertional mutagenesis, specifi-
cally oncogene activation. Clearly, the production of rep-
lication competent virus not only creates the potential of
pathogenetic disease, but will also greatly increase the
probability of insertional mutagenesis. In fact, in the one
instance where a vector contaminated with a replication
competent virus was administered to animals viral repli-
cation per se did not appear to have an overt pathogenetic
affect, rather a T-cell lymphoma eventuated [62], presum-
ably as a result of oncogene activation. Although these
conclusions are obvious and widely acknowledged it is
reassuring to know that there appear to be no retroviral
pathogenetic mechanisms of general relevance to the
safety, or otherwise, of retroviral vector systems that have
been overlooked.
While the inadvertent transfer of gag, env and other retro-
viral genes also has the potential of inducing a pathoge-
netic state this would appear to depend on the specific
retroviral gene sequence in question and to not be of gen-
eral significance. Even so, minimizing the inadvertent
transfer of retroviral gene sequences should clearly be an
objective when developing retroviral vectors, not only
because of this issue but also because it will have a bearing
on the likelihood of replication competent virus being
produced and of an endogenous retrovirus being
activated.
In addition, even though oncogene capture by retrovi-
ruses is an extremely rare event, the very significant path-
ogenic potential of the viruses that result means that it
should also be taken into consideration during the devel-
opment of retroviral vector systems.
For various reasons, not least of which has been the prob-
lem of achieving positive experimental outcomes, only
the issue of reducing the probability of replication compe-
tent virus arising has been systematically addressed during
the development of retroviral vector technology. Indeed,
great care has been taken in the development of retroviral
vector systems to minimise the chance of producing repli-
cation competent retroviruses [63,64]. However,
although clear means of doing so have been described
[13,14,65], the need to minimize the probability of onco-
gene activation has often been made secondary to the
issue of efficient transgene expression [66]. This has espe-
cially been the case with oncogenic retroviral vectors
where transcriptional silencing has been a major problem
[67].
Replication competent virus
The generation of replication competent virus has, from
the very beginning, been seen as the major safety issue for
retroviral vectors and this has led to a prolonged effort to
develop means of minimising the probability of it arising.
There are two principal ways in which replication compe-
tent virus can be produced. The first of these is through
recombination of the constituent parts of the vector sys-
tem (i.e. vector and helper trans function plasmids), either
with themselves or with endogenous viral sequences in
the cell lines used for virus production [15,16]; the second
is by activation of an endogenous proviral sequence. The
first of these issues has been addressed by (i) breakdown
of helper functions onto different plasmids; (ii) manipu-
lation of codon usage in helper plasmids; (iii) removal, or
mutagenesis, of unnecessary cis sequences present in the
vector; (iv) the development of SIN vectors; (v) the mini-
misation of homology between the separate plasmids that
make up the system; and (vi) the use of cell lines that do
not contain endogenous retroviral sequences with homol-
ogy to the vector system [13,14,63-65]. Although for
many vector systems each of these approaches requires
further refinement, in principle, they clearly provide the
basis for the construction of vector systems where the
probability of replication competent virus being pro-
duced via any of these mechanisms appears to be remote.
While this doesn't negate the need for appropriate quality
control procedures, especially as there is still the remote
probability of inadvertent activation of an endogenous
retrovirus from the cell line used for virus production, it
means that the major safety issue faced by those wishing
to use retroviral vectors is that of insertional mutagenesis
and oncogene activation.
Insertional mutagenesis and oncogene activation
As discussed above, oncogene activation can occur either
by transcription from one of the proviral LTRs, or by acti-
vation of an endogenous promoter by provision of tran-
scriptional enhancer elements. The transgene aside, these
events would appear to depend absolutely on the pres-
ence of active transcriptional control elements in the viral
LTRs as evidenced by the critical role LTR sequences play
in determining the ability of most non-defective retrovi-
ruses to induce cancers, and in determining the tissue spe-
cificity of cancer induction. There is no evidence that
retroviruses contain transcriptional control elements of
significance in other parts of their genomes. Therefore, the
main approaches to minimizing the probability of onco-
gene activation must be the development of vectors from
non-oncogenic retroviruses, the careful development of
the SIN vector principal, and careful consideration of theGenetic Vaccines and Therapy 2004, 2:9 http://www.gvt-journal.com/content/2/1/9
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promoter used to drive transcription of the transgene (see
below).
Retroviral gene transfer
The minimization of the inadvertent transfer of retroviral
genes to target cells is clearly a worthwhile objective as
some of these genes have direct pathogenic potential and
they may also influence the probability of endogenous
retroviral sequences in the target cell being activated. Gen-
erally, the principles applied to the design of vector sys-
tems in order to minimize the probability of RCR being
produced will also minimize the probability of inadvert-
ent retroviral gene transfer. However, as the production of
RCR requires multiple recombination events more effort
should be made to analyse the rate of transfer and expres-
sion of individual retroviral gene sequences by vector sys-
tems. It is clear that the rate of individual gene transfer is
much higher than the rate of RCR generation and can
occur at a significant frequency even in highly evolved sys-
tems where RCR cannot be detected [68]. This suggests
that further efforts need to be made to assess and reduce
the rate of transfer of retroviral genes.
Oncogene capture
The mechanism of oncogene capture appears to be
dependent on the generation of a chimeric retroviral-
oncogene transcript (69, 70). This suggests that the risk of
oncogene capture will be related to the efficiency of termi-
nation/polyadenylation of the proviral transcript and that
this should be considered and assessed in the process of
vector development, especially as retroviral polyadenyla-
tion sequences are often relatively inefficient, perhaps
reflecting the necessity for the polyadenylation signal to
be inactive in the context of the 5' LTR. However, in tran-
sient virus production systems, where the transfected vec-
tor plasmid presumably remains either entirely, or almost
entirely extrachromosomal, this mechanism would
appear to preclude the probability of oncogene capture. In
the case of stable producer cell lines there is clearly an
argument for categorizing the integration site of the vector
sequence and discarding any clones where this is in a
known or suspected oncogene.
Adverse events in animal experiments and clinical trials
The adverse events that have been observed in animal
experiments and clinical trials reinforce the conclusions
discussed above, that replication competent virus [62]
and insertional mutagenesis [71,72] are the two risk fac-
tors of significance in retroviral mediated gene therapy.
The two known instances where insertional mutagenesis/
oncogene activation has resulted from the administration
of a replication defective retroviral vector suggest that, the
design of the vector aside, there are additional risk factors
that influence the probability of an adverse event, the
most obvious of these being the specific transgene
expressed from the vector [71,73,74] which in both cases
is a gene capable of influencing cell growth (although in
neither case can it be considered a classical oncogene). In
terms of the influence of vector design it is interesting to
note that in both of these instances the same vector,
pMFG [66] was used [75,76]. This vector is derived from
MoMLV, a strongly oncogenic murine retrovirus, and
notably uses the viral LTR to drive expression of the
transgene. In both cases the vector appears to have been
chosen primarily for its ability to efficiently drive trans-
gene expression in haematopoietic lineages without con-
sideration that this may also select for an increased risk of
oncogene activation. Given the historical difficulty of
obtaining good transgene expression from MoMLV
derived vectors in haematopoietic lineages, and the lack of
evidence to suggesting that oncogene activation was a sig-
nificant safety issue with replication defective MoMLV
vectors, it is not surprising that this approach was taken.
Indeed, it is generally believed that, in general, the risk of
insertional mutagenesis, while poorly defined, is proba-
bly substantially lower than seen in the X-SCID trial [77]
where there appear to be a number of specific secondary
risk factors [72-74]. In the absence of such secondary risk
factors it is unclear what the real risk is; given the complex-
ity of cellular and genetic regulatory processes and net-
works it is also unclear how many apparently innocuous
transgenes will in fact increase the risk of adverse effects
when expressed in a constitutive manner. However, no
adverse events have been reported for the long running
ADA-SCID trial where mature T-cells were targeted [78] or
in PBL and PHSC targeted gene therapy for the same con-
dition [79], although in both cases the number of patients
who have been treated is very small. In all these protocols
a non-self inactivating MoMLV derived vector was used.
However, even with these unknowns it is apparent that
improvements in vector technology, such as the use of SIN
vectors, will greatly reduce the risk, whether or not addi-
tional risk factors are present.
In terms of the vector technology used on the two occa-
sions where oncogene activation has been observed the
following comments can be made:
1) The vector is derived from MoMLV and uses the LTR
sequence to drive the transgene via splicing. MoMLV is a
strongly oncogenic, non-defective virus that causes B-and
T-cell lymphomas and leukemias in mice. As with other
non-defective oncogenic retroviruses the primary determi-
nant of its pathological properties is the long terminal
repeat enhancer. MoMLV has been shown to induce onco-
genesis via activation of any one of a number of different
cellular genes (Ahi1, Bla1, Bmi1, Cyclin D2, Dsi1, Emi1,
Ets1, Evi1, Gfi1, c-Ha-ras, Lck, Mis2, Mlvi2, 3 and 4, c-myb,
c-myc, N-myc, Notch1, Pal1, Pim1 and 2, prolactin recep-
tor, Pvt1, Tiam1 and Tpl2).Genetic Vaccines and Therapy 2004, 2:9 http://www.gvt-journal.com/content/2/1/9
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2) The vector LTR is used to control transcription of the
transgene. In the case of the X-SCID trial there is a strong
selective pressure for gene corrected cells and accordingly
there will clearly be an equally strong selection for trans-
duced T-cell clones in which the LTR is active.
3) The PHSC is notoriously difficult to transduce with
oncogenic retroviral vectors and the protocol used was
designed to enhance transduction by using multiple
cytokines to stimulate division of PHSC. This is likely to
induce many genes involved in regulating cell growth. As
retroviruses preferentially integrate into active gene
sequences, this would increase the number of growth reg-
ulating genes accessible as targets for provirus integration
and hence promiscuous, unregulated activation. Specifi-
cally, LMO2, the oncogene activated in the X-SCID trial, is
normally expressed in primitive haematopoietic cells (the
target for gene transfer) but not in mature cells (80).
Therefore, it will be accessible for proviral integration dur-
ing the transduction process and its continuing expression
in maturing T cells generated from gene corrected precur-
sors is biologically inappropriate.
The problems that occurred in this X-SCID trial, their
broader relevance and possible answers, have all been
reviewed from a number of aspects [72,73,77]. However,
the focus has been on the biology of the system, and little
attention has been paid to how technological changes in
vector delivery systems and protocols might impact on the
risk of insertional mutagenesis/oncogene activation.
Given what is known about retroviral mediated inser-
tional mutagenesis it is surprising that more attention has
not been paid to the technology used in many of the ret-
roviral mediated gene therapy animal studies and human
trials. With hindsight, it seems that the technologies used
were selected on the basis of efficacy, not safety, that is
achieving adequate gene expression took preference over
consideration and assessment of insertional mutagenesis.
However, given the technical difficulties involved in
developing a workable protocol this is not surprising, and
it is a pre-occupation that was, and is, shared by all gene
therapy researchers.
Possible technological approaches that would appear to
provide answers to these issues include:
1) The use of self-inactivating (SIN) vectors would make a
major difference in that the provirus would lack all U3
enhancer sequences, negating the ability of the LTR to
activate cellular genes. The vector should also not contain
active splice signals. However, given the ability of SIN vec-
tors to be repaired at a significant rate during virus pro-
duction (see below) careful selection of the retrovirus
used to build the vector backbone is also important if this
risk is to be minimised. Clearly the construction of vectors
from non-oncogenic retroviruses and the development of
more effective (i.e. less prone to LTR repair) SIN vectors is
warranted. If SIN vectors are to be used the transgene must
be expressed from an internal promoter which must also
be presumed to have the potential for oncogene
activation. Therefore it would be preferable to use a pro-
moter without highly active enhancer elements. In addi-
tion, the wisdom of incorporating matrix/scaffold
attachment regions into vectors to increase expression
may also be contraindicated as these sequences have long-
range enhancer like properties (81). If high levels of gene
product are required, consideration should be given to
other means to enhance transgene expression, such as
codon-optimisation of coding sequences.
2) Vectors should be developed from non-oncogenic ret-
roviruses. The recent development of vectors from HIV-1
and other lentiviruses for unrelated reasons (predomi-
nantly their ability to transduce non-cycling cells) means
that this has already happened. The Tat dependence of the
HIV-1 LTR may also provide an extra measure of safety as
long as Tat is not transferred along with the vector. How-
ever, the enhancing properties of the HIV-1 LTR in the
presence and absence of Tat needs to be carefully defined
in order to test the assumption that the HIV-1 LTR lacks
the ability to trans-activate adjacent promoters. The differ-
ent integration specificities of lentiviral (centrally in active
gene sequences) and oncogenic (promoter adjacent in
active gene sequences) retroviruses and vectors [82] also
give reason to suppose that the former may be less likely
to cause oncogene activation. However, this remains to be
directly demonstrated.
3) The incorporation of strong transcription termination/
polyadenylation signals and gene isolator sequences (83)
may provide another means to reduce the possibility of
adjacent genes being activated. These sequences should
also reduce the probability of oncogene capture in virus
producer cells. However, the incorporation of insulator
sequences appears to lead to a significant loss of vector
titre (84).
4) When the transgene plays a role in regulating cell
growth, extra consideration should be given to using the
relevant control signals from the gene in question to reg-
ulate expression of the transgene.
5) Although the PHSC is theoretically a very attractive tar-
get for gene transfer it is extremely difficult to transduce
with retroviral vectors derived from oncogenic viruses
such as MoMLV. Although efficient transduction of
human PHSC can now be achieved this requires exposure
to multiple cytokines over a relatively long culture period.
The potential of new retroviral vectors derived fromGenetic Vaccines and Therapy 2004, 2:9 http://www.gvt-journal.com/content/2/1/9
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lentiviruses (85) and spumaviruses (86) to transduce
PHSC with shorter exposure to less cytokines needs to be
fully explored.
6) In general the limitations of vectors should be taken
into account when designing gene therapy protocols. For
example, in the case of X-SCID, it may be just as effica-
cious to target a more committed T-cell precursor that can
be transduced more easily, and without biological manip-
ulation using multiple cytokines. Alternatively, if the
PHSC is to be targeted as highly enriched a PHSC popula-
tion as possible should be used in order to expose the
patient to the minimum number of transduction events
compatible with the desired outcome. In the two X-SCID
patients who developed T cell leukemia, molecular analy-
sis of samples collected before the appearance of
malignant disease showed the presence of >50 γc trans-
duced T cell clones. Approximately 14 to 20 million trans-
duced CD34+  cells were infused into these patients.
Therefore, it would appear the patient is exposed to a
much greater number of transduced cells than is theoreti-
cally necessary to produce the desired result. In other
words, the process of generating gene corrected T cell
clones by transduction of CD34+ cells is very inefficient.
SIN vectors, how good are they?
With hindsight SIN vectors [13,87,88] now appear likely
to be one of the most important general developments in
retroviral vector technology since the advent of replication
defective vector systems in the 1980s. SIN vectors take
advantage of the reverse transcription reaction in which
the U3 region of the 3' LTR acts as the template for the U3
region in both LTRs of the provirus. As the transcriptional
enhancer elements in the 3' LTR are redundant in the con-
text of a retroviral vector construct they can theoretically
be deleted without affecting vector performance. After
transduction of the target cell both LTRs are deleted and
are transcriptionally silent. Although this requires that an
internal promoter is used to control expression of the
transgene, and makes it more difficult to generate high
titre stable packaging cell lines, the advantages of the
approach are obvious. However, SIN vectors have not
been widely used in the case of oncogenic retroviral vec-
tors, principally because viral titres were low, because of
high rates of repair of the SIN deletion [13,89] and
because of negative effects of the SIN deletion on gene
transfer efficiency [90]. Subsequently, by the use of a het-
erologous promoter in the 5' LTR an effective SIN vector
based on spleen necrosis virus was developed [91] but this
vector has not been widely utilized to date.
In contrast, SIN vectors have been widely adopted in the
lentiviral vector field [14,65,92,93] where transient
expression systems are generally used to produce virus,
avoiding the difficulties of making stable cell lines associ-
ated with SIN vectors. In addition, in terms of transgene
expression, lentiviral SIN vectors appear to perform as
well as, if not better than, vectors with an intact 3' LTR
[93,94]. However, even with vectors with large 3' LTR
deletions it is obvious that repair of the SIN deletion also
occurs at a significant rate with lentiviral SIN vectors
[14,92]. Therefore, while the concept of SIN vectors is a
powerful one, further development and rigorous testing
of this technology is required before it can be confidently
used to address the problems of insertional mutagenesis.
Conclusion
The most important determinant of the safety of retroviral
vectors remains ensuring they are free of replication com-
petent retrovirus of any sort. Clearly, the technologies
available for the production of vector virions would
appear able to preclude the production of replication
competent virus by recombination of the constituent
parts of the vector system (i.e. vector and helper plasmids)
with a very high degree of certainty. However, production
of replication competent virus from the cell lines used for
virus production remains a theoretical possibility and
more work needs to be done on generic assays for replica-
tion competent retroviruses.
Apart from the issue of replication competent virus, anal-
ysis of the pathologies associated with retroviruses, and
the results of the X-SCID trial, demonstrate that careful
attention must be paid to the ability of sequences in retro-
viral vectors to activate transcription of genes adjacent to
proviral integration sites. Although the use of SIN vectors
will greatly reduce the risk of such events, given the predi-
lection of current SIN vectors to be repaired during virus
production these vectors need to be further developed,
especially for vectors derived from strongly oncogenic
viruses. In addition, inadvertent transfer to, and expres-
sion in, transduced cells of gag, env (SU) and other retro-
viral gene sequences would appear to of relevance and
needs to be specifically addressed in the development of
vector systems.
As both oncogenic (MoMLV derived) and lentiviral (HIV-
1 derived) vectors have been shown to preferentially inte-
grate into transcribed sequences it would appear logical
that the likelihood of proviral integration near cellular
genes involved in the positive regulation of cell growth
would be increased in actively growing cell populations.
This suggests that the use of transduction protocols that
target non-cycling cells, or cells that are subjected to the
minimum of stimulatory signals as is compatible with
efficient gene transfer, would be greatly advantageous in
terms of minimising the risk of malignant events after the
stimulatory signals are removed.Genetic Vaccines and Therapy 2004, 2:9 http://www.gvt-journal.com/content/2/1/9
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With hindsight, the observation of malignant events
induced by replication defective MoMLV retroviral vectors
is not surprising although the frequency of these events in
the X-SCID gene therapy trail certainly was. The concern is
that these events will now cause a significant backlash
against the use of all retroviral vectors while the real mes-
sage is that we need to make better use of the knowledge
we now have in terms of designing vectors and gene ther-
apy protocols. Clearly, the known oncogenic potential of
MoMLV and its relationship to viral sequences has, for
one reason or another, been largely ignored to date.
Indeed, most of the retroviral vectors used in trials to date
are based on MoMLV and contain an intact 5' LTR. While
the historic reasons for this are obvious we now need to
evaluate and adopt more appropriate technologies as rap-
idly as possible.
There are several obvious conclusions to be drawn from
the X-SCID trial and the results of Li et al [71]. The first is
that in the absence of additional risk factors the risk of
malignant events resulting from exposure to a replication
defective retroviral vector is low but remains to be accu-
rately quantified. Secondly, what constitutes an addi-
tional risk factor is hard to predict, making risk assessment
difficult. However, even with these unknowns, there exist
technological approaches that should greatly reduce the
risks associated with retroviral mediated gene therapy.
These include SIN vectors and new types of retroviral vec-
tors (namely lentiviral vectors) that may allow simpler
transduction protocols that perturb the normal state of
the target cell less than current approaches. This is espe-
cially true when the PHSC is the target of gene transfer;
current protocols using oncogenic retroviral vectors rely
heavily on manipulating the state of the target cell by
exposure to multiple cytokines over relatively long peri-
ods. These protocols are also relatively inefficient; this
reflects the poor match between the target cell and prop-
erties of these vectors. In contrast, vectors derived from
lentiviruses and spumaviruses appear to allow more effi-
cient transduction of PHSC with less requirement for
cytokine stimulation of the target cells [85,86,95-97]. It is
of note that the use of lentiviral vectors may also be
preferable in other ways. Not only do they have uniquely
positive properties as gene therapy vectors, there is no evi-
dence that the viruses from which they are derived are able
to induce gene activation using the same mechanisms as
used by non-defective oncogenic retroviruses.
Regulatory authorities also have a role to play. Clinical tri-
als are based on extensive preclinical experimentation and
animal trials that take many years to complete. Clearly,
the particular vector system that has been used to develop
a protocol may no longer be the best to use ten years later
when clinical trials become a reality. The question is, then,
how can the regulation of clinical trials be made flexible
enough to allow the introduction of new and improved
vector technology late in the process?
In conclusion, retroviral mediated gene transfer remains
an extremely attractive option for gene therapy when the
stable and permanent genetic modification of the target
cell is optimal. However, we must take greater care, and
utilise more resources, for the pro-active, rather than reac-
tive, refinement and testing of the basic technology that is
used for gene therapy and for the adoption of improved
vector systems if adverse events are to be minimised.
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